Global Launch of Lubripharm™ Pro: SPI and Anek Prayog Form Strategic Partnership
17 February 2026
SPI and Anek Prayog Partner to Bring Lubripharm™ Pro Sodium Stearyl Fumarate to the Global Market
WILMINGTON, DE - SPI Pharma, Inc. (SPI), a global leader in providing specialized solutions to the pharmaceutical and nutraceutical industry, is excited to announce a new global distribution partnership with Anek Prayog, India under which SPI will exclusively sell, promote, and distribute Lubripharm™ Pro SSF, a next-generation sodium stearyl fumarate lubricant manufactured by Anek Prayog. This global distribution agreement is effective immediately, with product launch scheduled for February 24.
Lubripharm Pro SSF delivers consistent performance, superior compactability, and reliable manufacturability—without the risks associated with magnesium stearate. Designed for sensitive and patient-centric formulations, it provides robust lubrication with low blending sensitivity, better compaction, superior API compatibility, faster disintegration, and reliable dissolution performance. The product supports a wide range of dosage forms and is optimized for modern manufacturing processes, including direct compression, granulation, and continuous processing.
“This partnership reflects SPI’s continued focus on expanding our portfolio with high-performance excipients that address real formulation challenges. By combining Lubripharm Pro SSF with our formulation expertise, we are further strengthening our ability to deliver reliable, differentiated solutions to customers worldwide.” said Joe Matt, VP EADDS of SPI Pharma.
“We are delighted to collaborate with SPI for Lubripharm Pro SSF. By combining our extensive manufacturing experience and strong regulatory support with SPI’s deep technical expertise in the pharmaceutical industry and their specialization in excipient marketing tailored to customer needs, we are confident that this partnership will achieve a high level of business success across global markets. Together, we look forward to delivering quality, innovation, and value to customers worldwide.” Dinesh Gurav, Director of Anek Prayog-India.
About SPI Pharma
SPI Pharma, headquartered in Wilmington, Delaware, USA, provides innovative solutions to global pharmaceutical and nutritional customers. Product lines include Antacid Actives, Excipients, Drug Delivery Systems, Taste-Masking, and Vaccine Adjuvants. SPI Pharma specializes in drug development services, having participated in over 60 commercially launched and marketed drugs globally. With its sites in the United States, France, and India, the company solves the most challenging formulation problems –– efficiently, cost-effectively, and with a focus on service.
About Anek Prayog
Anek Prayog is a 53-year-old company engaged in the manufacturing of bulk drugs and excipients in India. Our state-of-the-art manufacturing facility holds multiple international regulatory accreditations includes EDQM/EU, WHO, and ANVISA (with regular inspections), as well as USFDA, COFEPRIS, and MFDS in the past.
We are pioneers in India for SSF, with over 30 years of manufacturing experience. SSF is produced in a dedicated facility in full compliance with ICH and PIC/S guidelines ensuring consistent quality and reliability. We are committed to maintaining superior standards of quality, safety, and compliance in line with international requirements, while fostering long-term partnerships built on trust and performance.
Contact:
Amanda Coulter (Head of Global Marketing – SPI Pharma)